career in nephrology, which to him always has been a fascinating field. It is intertwined with many other specialties of medicine including endocrinology, and some of our colleagues including Professor Hartmut Neumann are board certified in both endocrinology and nephrology [1] . Systemic disorders such as diabetes mellitus and autoimmune disease can affect the kidneys, and vice versa, disorders (such as renal osteodystrophy) can ensue on the basis of acute or chronic kidney disease. Chronic kidney disease worldwide has been reported to be prevalent in 10% to 15% of the general population, and the treatment of patients with kidney disease represents a complex challenge [2, 3] . Endocrine disrupting chemicals including heavy metals may contribute to the development and progression of chronic kidney disease [4] [5] [6] . There is known considerable overlap between nephrology and endocrinology, borne by common pathophysiologic inter-relationships. Although the kidney plays a central role in body homeostasis, i.e., fluid and electrolyte balance, as well as regulatory control of blood pressure, one has to realize that it is not simply an excretory organ, as it exerts multiple endocrine functions, in fact, playing a significant role involving hormones involved in the renin-angiotensin-aldosterone system, erythropoietin, as well as 1,25 dihydroxy vitamin D3. Aside from producing enzymes, i.e., kallikreins, it also produces socalled local hormones, i.e., prostaglandins, endothelins, and adrenomedullin. Similarly, it is the primary target of other hormones, i.e., aldosterone, cortisol, angiotensin, and the natriuretic peptides [7, 8] .
With kidney disease being the 9th leading cause of death in the United States, it is important for clinicians to understand various endocrinological aspects that may affect such patients as it has crucial implications in management and prognosis.
I (CAK) am very delighted to introduce nephrology expert Dr. Edgar Lerma as the Guest Editor for this special issue of Reviews in Endocrine & Metabolic Disorders. Dr. Lerma has recently participated in a global expert conference on managing patients with diabetes and chronic kidney disease and has edited the book BChronic Kidney Disease and Hypertension^ [9, 10] . For this journal issue, Dr. Lerma assembled a panel of expert contributors from around the globe to discuss aspects of various endocrine disorders in patients with chronic kidney disease.
With the prevalence of diabetes around the world reaching epidemic proportions, the first set of articles in this issue is dedicated to this topic. Garla and colleagues [11] illustrate the challenges of glycemic management in patients with diabetes mellitus and chronic kidney disease. Hypoglycemia and glucose variability, especially in elderly, should be minimized [12] . Novel biomarkers for diabetic nephropathy and new insights into its pathophysiology are discussed by Ilyas and colleagues [13] . Besides diabetes mellitus, patients with chronic kidney disease have other factors, including hyperlipidemia, putting them at high risk for cardiovascular disease. Hager and colleagues [14] provide a nice overview on mechanisms underlying dyslipidemia in such patients and clinical trial evidence for lipid lowering therapy, discussing recently published guidelines pertaining to dyslipidemias as developed by various organizations, and how to apply them to everyday clinical practice.
The next series of articles is dedicated to electrolyte and water homeostasis, starting with an update on hyperkalemia including new therapeutic agents [15] . Disturbances in sodium and water balance including hyponatremia, hypernatremia, dehydration, and age-related kidney changes are then reviewed by Koch and Fulop [16] , followed by an excellent review on hyponatremia and bone disease by Negri and Ayus [17] , pointing out the importance to consider a bone density scan in patients with hyponatremia and to check a serum sodium concentration in (elderly) patients presenting with an orthopedic injury/fracture.
The third set of articles is related to bone in patients with chronic kidney disease, starting out with an overview of secondary hyperparathyroidism, including tools for its possible prevention [18] . With the increasing number of kidney transplantations in diabetic and other patients, it becomes important to understand pathophysiological processes posttransplantation such as osteoporosis which is reviewed by the nephroendocrinology team Gosmanova and Gosmanov [19] . Secondary causes of osteoporosis include hyperthyroidism, glucocorticoid excess, sex hormone deficiency, and others. Short stature not only can result from growth hormone deficiency, thyroid hormone deficiency, or glucocorticoid excess in childhood, but also from abnormalities in calciumphosphate homeostasis. Although he is an adult endocrinologist, CAK has received several consults for short stature, sometimes from grown men with BShort Man syndromeŵ hich in Wikipedia is reported as BNapoleon complex^and Bcharacterized by overly aggressive or domineering social behavior, driven by a perceived handicap to overcompensate in other aspects of their lives^(https://en.wikipedia.org/wiki/ Napoleon_complex). For individuals with short stature from X-linked hypophosphatemia, the most common form of hereditary rickets, there is potentially good news: treatment with growth hormone can accelerate longitudinal growth rate according to studies conducted by senior author Professor Santos. He and his colleagues provide an overview of this condition, summarizing current knowledge of phosphorus metabolism in individuals with X-linked hypophosphatemia and effects of fibroblast growth factor 23 on the epiphyseal growth plate of a mouse animal model [20] . The last two articles in this issue are dealing with abnormalities in the hypothalamo-pituitary-gonadal and the hypothalamopituitary-thyroid axis. Palmer and Clegg review sexual dysfunction in men and women with chronic kidney disease pointing out that successful kidney transplantation is the most effective way to restore normal sexual function in such patients [21] . Testosterone deficiency is regarded a risk factor for cardiovascular disease and testosterone therapy in selected patients can improve overall health with more data on this topic still evolving [22] [23] [24] [25] .
Iglesias and colleagues [26] conclude this guest issue and illustrate how challenging it can be to manage patients with chronic kidney disease and (abnormal) thyroid function tests.
